USE OF ¹⁷⁷Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER

Purpose of the study: to present current data regarding challenges in treatment of castration-resistant prostate cancer (CRPC) and the relationship between CRPC and the expression of prostate-specific membrane antigen (psma).

Material and Methods. The search for relevant sources was carried out in the Pubmed, elibrary, Medline databases. The review included 43 publications, most of which were published over the past 5 years.

Results. Currently, prostate cancer (PC) is one of the most common cancers in men. Moreover, over time, most patients develop resistance to therapy, which significantly worsens the prognosis of the disease. Psma is one of the molecular markers of prostate cancer; a number of studies have demonstrated a direct correlation between the level of psma expression and the tumor grade, stage and aggressiveness. Numerous studies indicate that psma represents an excellent target for radionuclide therapy of prostate cancer. ⁶⁸Ga or ¹⁸F-psma Pet/Ct is the most common method for diagnosing PC. It should be noted that modern trends in the development of nuclear medicine are closely related to theranostics; therefore, the creation of highly specific theranostic pairs for diagnosis and subsequent therapy of malignant tumors is of great significance. The data obtained indicate that ¹⁷⁷lu demonstrates the most optimal radiation and physical characteristics for therapeutic radionuclides, while psma-617 is one of the most studied ligands for radionuclide therapy.

Conclusion. Currently, there are several studies covering radionuclide therapy with various psmacompounds labeled with ¹⁷⁷lu. Radionuclide therapy with ¹⁷⁷lu-psma has been shown to be recommended for patients with metastatic CRPC, who have no benefits from alternative therapies or have contraindications to them.

1. Alekseev B.Ya., Nyushko K.M., Kaprin A.D. Second line chemotherapy in patients with castration-refractory prostate cancer. From clinical studies to practice. Cancer Urology. 2019; 15(1): 84–91. (in Russian).

2. Ahmadzadehfar H., Eppard E., Kürpig S., Fimmers R., Yordanova A., Schlenkhoff C.D., Gärtner F., Rogenhofer S., Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMADKFZ-617 of castrate- resistant metastatic prostate cancer. Oncotarget. 2016 Mar 15; 7(11): 12477–88. doi: 10.18632/oncotarget.7245.

3. Karyakin O.B., Kaprin A.D., Ivanov S.A. The national registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian Federation. Cancer Urology. 2019; 15(3): 78–88. (in Russian).

4. Gafanov R.A., Garmash S.V., Kravtsov I.B., Fastovets S.V. Metastatic castration-resistant prostate cancer: a current view on drug therapy and alternative tumor cell regulation. Cancer Urology. 2018; 14(1): 107–16. (in Russian).

5. Markova A.S., Matveev V.B., Nazranov B.M. Sequential therapy of metastatic castration-resistant prostate cancer: new possibilities. Cancer Urology. 2018; 14(3): 120–7. (in Russian).

6. Bellmunt J., Carles J., Albanell J. Predictive modelling in hormonerefractory prostate cancer (HRPC). Clin Transl Oncol. 2009 Feb; 11(2): 82–5. doi: 10.1007/s12094-009-0318-x.

7. Benešová M., Schäfer M., Bauder-Wüst U., Afshar-Oromieh A., Kratochwil C., Mier W., Haberkorn U., Kopka K., Eder M. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015 Jun; 56(6): 914–20. doi: 10.2967/jnumed.114.147413.

8. Freedland S.J., Richhariya A., Wang H., Chung K., Shore N.D. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology. 2012 Aug; 80(2): 293–8. doi: 10.1016/j.urology.2012.04.007.

9. Silver D.A., Pellicer I., Fair W.R., Heston W.D., Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997 Jan; 3(1): 81–5.

10. Pezaro C., Omlin A., Lorente D., Rodrigues D.N., Ferraldeschi R., Bianchini D., Mukherji D., Riisnaes R., Altavilla A., Crespo M., Tunariu N., de Bono J., Attard G. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014 Feb; 65(2): 270–273. doi: 10.1016/j.eururo.2013.10.055.

11. James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R., Ritchie A.W., Parker C.C., Russell J.M., Attard G., de Bono J., Cross W., Jones R.J., Thalmann G., Amos C., Matheson D., Millman R., Alzouebi M., Beesley S., Birtle A.J., Brock S., Cathomas R., Chakraborti P., Chowdhury S., Cook A., Elliott T., Gale J., Gibbs S., Graham J.D., Hetherington J., Hughes R., Laing R., McKinna F., McLaren D.B., O'Sullivan J.M., Parikh O., Peedell C., Protheroe A., Robinson A.J., Srihari N., Srinivasan R., Staffurth J., Sundar S., Tolan S., Tsang D., Wagstaff J., Parmar M.K.; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19; 387(10024): 1163–77. doi: 10.1016/S0140-6736(15)01037-5.

12. Poeppel T.D., Handkiewicz-Junak D., Andreeff M., Becherer A., Bockisch A., Fricke E., Geworski L., Heinzel A., Krause B.J., Krause T., Mitterhauser M., Sonnenschein W., Bodei L., Delgado-Bolton R.C., Gabriel M. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018 May; 45(5): 824–845. doi: 10.1007/s00259-017-3900-4.

13. Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987 Sep-Oct; 7(5B): 927–35.

14. Israeli R.S., Powell C.T., Corr J.G., Fair W.R., Heston W.D. Expression of the prostate-specific membrane antigen. Cancer Res. 1994 Apr 1; 54(7): 1807–11.

15. Chekhonin V.P., Grigorev M.E., Zhirkov Yu.A., Lebedev D.V. Prostatic specific membrane antigen and its role in the diagnosis of prostate cancer. Problems of Medical Chemistry. 2002; 48: 31–43. (in Russian).

16. Bouchelouche K., Choyke P.L., Capala J. Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discov Med. 2010 Jan; 9(44): 55–61.

17. Uprimny C., Kroiss A., Nilica B., Buxbaum S., Decristoforo C., Horninger W., Virgolini I.J. (68)Ga-PSMA ligand PET versus (18)F-NaF PET: evaluation of response to (223)Ra therapy in a prostate cancer patient. Eur J Nucl Med Mol Imaging. 2015 Feb; 42(2): 362–3. doi: 10.1007/s00259-014-2922-4.

18. Spatz S., Tolkach Y., Jung K., Stephan C., Busch J., Ralla B., Rabien A., Feldmann G., Brossart P., Bundschuh R.A., Ahmadzadehfar H., Essler M., Toma M., Müller S.C., Ellinger J., Hauser S., Kristiansen G. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018 Feb; 199(2): 370–377. doi: 10.1016/j.juro.2017.08.079.

19. Chatalic K.L., Veldhoven-Zweistra J., Bolkestein M., Hoeben S., Koning G.A., Boerman O.C., de Jong M., van Weerden W.M. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. J Nucl Med. 2015 Jul; 56(7): 1094–9. doi: 10.2967/jnumed.115.156729.

20. Chakraborty P.S., Kumar R., Tripathi M., Das C.J., Bal C. Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. Clin Nucl Med. 2015 Apr; 40(4): 328–9. doi: 10.1097/RLU.0000000000000709.

21. Gourni E., Henriksen G. Metal-Based PSMA Radioligands. Molecules. 2017 Mar 24; 22(4): 523. doi: 10.3390/molecules22040523.

22. Lütje S., Heskamp S., Cornelissen A.S., Poeppel T.D., van den Broek S.A., Rosenbaum-Krumme S., Bockisch A., Gotthardt M., Rijpkema M., Boerman O.C. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics. 2015 Oct 18; 5(12): 1388–401. doi: 10.7150/thno.13348.

23. Cho S.Y., Gage K.L., Mease R.C., Senthamizhchelvan S., Holt D.P., Jeffrey-Kwanisai A., Endres C.J., Dannals R.F., Sgouros G., Lodge M., Eisenberger M.A., Rodriguez R., Carducci M.A., Rojas C., Slusher B.S., Kozikowski A.P., Pomper M.G. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012 Dec; 53(12): 1883–91. doi: 10.2967/jnumed.112.104661.

24. Bragina O.D., Chernov V.I., Lar’kina M.S., Zelchan R.V., Sinilkin I.G., Medvedeva A.A. Prostate specific membrane antigen: current possibilities in the diagnosis of prostate cancer. Molecular Medicine. 2018; 16(4): 3–8. (in Russian).

25. Dolgushin M.B., Meshcheryakova N.A., Odzharova A.A., Matveev V.B., Nevzorov D.I., Platonova O.E., Kochergin P.V. 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography in the diagnosis of recurrent prostate cancer: clinical observation. Cancer Urology. 2018; 14(3): 134–138. (in Russian). doi: 10.17650/1726-9776-2018-14-3-134-138.

26. Ignatova М.V., Tlostanova М.S., Stanzhevsky А.А. The first experience of performing combined positron-emission with computed tomography with prostate-specific membrane antigen labeled with gallium-68 in patients with minimal level of prostate-specific antigen after radical prostatectomy. Problems in Oncology. 2018; 64 (4): 508–514. (in Russian).

27. Larenkov A.A., Kodina G.E. Radionuclide Diagnosis of Prostate Cancer: Positron Emission Tomography with 68Ga-PSMA Inhibitors and Their Pharmaceutical Development. Medical Radiology and Radiation Safety. 2017; 62(6): 58–74. (in Russian).

28. Poyda M.D., Ryzhkova D.V., Stanzhevsky A.A. 68Ga-PSMA- labeled biomarker for positron emission tomography (literature review). Translational Medicine. 2018; 5(5): 46–52. (in Russian).

29. Eiber M., Maurer T., Souvatzoglou M., Beer A.J., Ruffani A., Haller B., Graner F.P., Kübler H., Haberkorn U., Eisenhut M., Wester H.J., Gschwend J.E., Schwaiger M. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015 May; 56(5): 668–74. doi: 10.2967/jnumed.115.154153.

30. Afshar-Oromieh A., Haberkorn U., Schlemmer H.P., Fenchel M., Eder M., Eisenhut M., Hadaschik B.A., Kopp-Schneider A., Röthke M. Comparison of PET/CT and PET/MRI hybrid systems using a 68Galabelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014 May; 41(5): 887–97. doi: 10.1007/s00259-013-2660-z.

31. Rahbar K., Weckesser M., Huss S., Semjonow A., Breyholz H.J., Schrader A.J., Schäfers M., Bögemann M. Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer. J Nucl Med. 2016 Apr; 57(4): 563–7. doi: 10.2967/jnumed.115.169243.

32. Chernov V.I., Bragina O.D., Zelchan R.V., Medvedeva A.A., Sinilkin I.G., Larkina M.S., Stasyuk E.S., Nesterov E.A., Skuridin V.S. Labeled Somatostatin Analogues in Theranostics of Neuroendocrine Tumors. Medical Radiology and Radiation Safety. 2017; 62(3): 42–49. (in Russian).

33. Varlamova N.V., Skuridin V.S., Nesterov E.A., Chernov V.I., Titskaya A.A. Studying acute toxicity of new radiopharmaceutical 99mTcAl 2O3 nanocolloids for oncological diagnostics. Experimental and Clinical Pharmacology. 2015; 78(6): 26–29. (in Russian).

34. Zeltchan R., Medvedeva A., Sinilkin I., Bragina O., Chernov V., Stasyuk E., Rogov A., Il’ina E., Larionova L., Skuridin V., Dergilev A. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis. IOP Conference Series: Materials Science and Engineering. 2016; 012054.

35. Zechmann C.M., Afshar-Oromieh A., Armor T., Stubbs J.B., Mier W., Hadaschik B., Joyal J., Kopka K., Debus J., Babich J.W., Haberkorn U. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014; 41(7): 1280–92. doi: 10.1007/s00259-014-2713-y.

36. Rathke H., Flechsig P., Mier W., Bronzel M., Mavriopoulou E., Hohenfellner M., Giesel F.L., Haberkorn U., Kratochwil C. Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617. J Nucl Med. 2019 Jun; 60(6): 806–811. doi: 10.2967/jnumed.118.218917.

37. Kratochwil C., Bruchertseifer F., Rathke H., Bronzel M., Apostolidis C., Weichert W., Haberkorn U., Giesel F.L., Morgenstern A. Targeted α-herapy of Metastatic Castration-Resistant Prostate Cancer with 225AcPSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2019 Jun; 60(6): 806–811. doi: 10.2967/jnumed.117.191395.

38. Okamoto S., Thieme A., Allmann J., D’Alessandria C., Maurer T., Retz M., Tauber R., Heck M.M., Wester H.J., Tamaki N., Fendler W.P., Herrmann K., Pfob C.H., Scheidhauer K., Schwaiger M., Ziegler S., Eiber M. Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. J Nucl Med. 2017 Mar; 58(3): 445–450. doi: 10.2967/jnumed.116.178483.

39. Rahbar K., Schmidt M., Heinzel A., Eppard E., Bode A., Yordanova A., Claesener M., Ahmadzadehfar H. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. J Nucl Med. 2016 Sep; 57(9): 1334–8. doi: 10.2967/jnumed.116.173757.

40. Rahbar K., Ahmadzadehfar H., Kratochwil C., Haberkorn U., Schäfers M., Essler M., Baum R.P., Kulkarni H.R., Schmidt M., Drzezga A., Bartenstein P., Pfestroff A., Luster M., Lützen U., Marx M., Prasad V., Brenner W., Heinzel A., Mottaghy F.M., Ruf J., Meyer P.T., Heuschkel M., Eveslage M., Bögemann M., Fendler W.P., Krause B.J. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017 Jan; 58(1): 85–90. doi: 10.2967/jnumed.116.183194.

41. von Eyben F.E., Roviello G., Kiljunen T., Uprimny C., Virgolini I., Kairemo K., Joensuu T. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018; 45(3): 496–508. doi: 10.1007/s00259-017-3895-x.

42. Kratochwil C., Fendler W.P., Eiber M., Baum R., Bozkurt M.F., Czernin J., Delgado Bolton R.C., Ezziddin S., Forrer F., Hicks R.J., Hope T.A., Kabasakal L., Konijnenberg M., Kopka K., Lassmann M., Mottaghy F.M., Oyen W., Rahbar K., Schöder H., Virgolini I., Wester H.J., Bodei L., Fanti S., Haberkorn U., Herrmann K. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019 Nov; 46(12): 2536–2544. doi: 10.1007/s00259-019-04485-3.

43. Strosberg J., El-Haddad G., Wolin E., Hendifar A., Yao J., Chasen B., Mittr]a E., Kunz P.L., Kulke M.H., Jacene H., Bushnell D., O'Dorisio T.M., Baum R.P., Kulkarni H.R., Caplin M., Lebtahi R., Hobday T., Delpassand E., Van Cutsem E., Benson A., Srirajaskanthan R., Pavel M., Mora J., Berlin J., Grande E., Reed N., Seregni E., Öberg K., Lopera Sierra M., Santoro P., Thevenet T., Erion J.L., Ruszniewski P., Kwekkeboom D., Krenning E.; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2): 125–135. doi: 10.1056/NEJMoa1607427.